Blog

3.0 High-Efficiency NK Serum-Free Culture Kit | Chapter 1: Cord Blood–Derived CBNK

Release Date:

2026-02-27 16:51

Hycells Biotechnology’s newly launched 3.0 High-Efficiency Serum-Free NK Cell Culture Kit (Catalog No.: NK888-2L), in collaboration with the CBMC Seed Bank, provides a comprehensive, integrated cell culture solution: from thawing and recovering CBMC seed stocks or directly and efficiently expanding fresh CBMCs, to ultimately obtaining NK cells with high purity and high viability. This integrated culture system supports flexible expansion based on cell status, with a scalable culture volume of up to 10 liters, delivering outstanding culture performance and exceptional cost-effectiveness, and earning widespread trust and recognition from customers.

 

Hycells Biological 3.0 High-Efficiency Version HiXpan Registered trademark The NK serum-free culture kit is manufactured in strict compliance with Good Manufacturing Practice (GMP) and its production system meets relevant guidelines, including the “818 Requirements,” making it suitable for pharmaceutical-grade production and applications.

Sharing of NK Cell Culture Data Derived from Umbilical Cord Blood

 

Sample source: Ten random fresh or cryopreserved CBMC samples from the Hycells Biological Cell Bank.

NK Kit Catalog Number: NK888-2L

Initial cell count: 38 million–65 million

Cell yield: 15–25 billion

Purity of harvest: 95%–99%

Magnification: 200x–500x

 

The fluid replacement procedure is shown in the figure below:

 

Sample 1 (Frozen CBMC)

2511005-D7-220 million

2511005-D19-15.5 billion

 

Sample 2 (Frozen CBMC)

2511007-D7-250 million

251,100,700,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,......251,100,700,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000......

 

Sample 3 (Frozen CBMC)

2511011-D7-330 million

251,101.1 million – 18 – 15.84 billion

 

Sample 4 (Frozen CBMC)

251,200,400 - D7 - 240 million

 

251,200,400,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,0......251,200,400,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,......

 

Sample 5 (Frozen CBMC)

251,200,500 - D7 - 170 million

251,200,500,000 – D20 – 16.8 billion

 

Sample 6 (Frozen CBMC)

251,200,800 - D7 - 350 million

251,200,800,000 - D16 - 18.8 billion

 

Sample 7 (Frozen CBMC)

251,200,900 - D7 - 440 million

251,200,9-D17-15.6 billion

 

Sample 8 (Fresh CBMC)

XSCB20260116001-D7-382 million

XSCB20260116001-D18-23.1 billion

 

Sample 9 (Fresh CBMC)

XSCB260117G-D7-397 million

XSCB260117G-D18-25.3 billion

 

Sample 10 (Fresh CBMC)

CBMC26010203-D7-352 million

CBMC26010203-D16-16.6 billion

 

Live Announcement: Integrated Culture of NK Cells

 

Hycells Biotechnology cordially invites you to join the “Hycells NK Cell Integrated Culture Live Stream,” where we will explore the complete closed-loop process—from sample collection to the production of high-quality cells.

 

How does Hycells Biotech achieve “one-stop” NK cell culture, streamline the operational workflow, and reduce the risk of contamination? Its proprietary culture system enables high-density expansion of NK cells from a wide range of sample types, with purity exceeding 95%. Technical experts will be live in the broadcast room to address practical challenges in NK cell culture, such as aggregation, slow expansion, and low activity. We simplify processes through cutting-edge technology and validate our capabilities with robust data. On March 10, Hycells invites you to join us in the live stream.

 

Previous page

Live Stream Preview | Integrated NK Cell Culture Protocol: A Comprehensive Analysis from Process Development to Application

New Product | Hycells Announces the Launch of High-Viability Primary Hepatocyte Cells!

Next page

Related News

HiXpan® Cell Culture Additive: Answers to Key Questions (Part 2)

Hycell’s maximum production capacity per batch is 200–400 units of the 500 mL format, ensuring stable supply and meeting customers’ ongoing production needs.

HiXpan® Cell Culture Additive: Key Questions and Answers (Part 1)

The blood‑derived raw materials used in HiXpan® cell culture additives comply with all regulatory requirements throughout collection, ethical review, informed consent, and commercial authorization, and are supported by a fully traceable supply chain.

(3) Batch Stability and Performance Verification | Upholding Quality, Striving for Progress While Maintaining Stability

This paper focuses on how Hycells transforms biological variability into engineering‑level determinism through a scientifically informed blending strategy and stringent control at the collection end.

(II) Security Assurance Section | Safety First, Defense Prioritized

Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.

(1) Compliance and Traceability Section | Establishing a Foundation of Compliance, Ensuring Source Tracing

This article will examine how Hycells proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.

Compliance as the Foundation, Safety as the Core | The Steadfast Commitment and Confidence Behind Heyou Sheng’s Serum Substitute

In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.